Five Pharma majors to collab for clinical trial of Molnupiravir drug

Jun 29, 2021, at 11:54 pm

Hyderabad/UNI: Five Indian pharmaceutical majors joined hands to hold the clinical trial of the investigational and oral anti-viral drug Molnupiravir that inhibits the replication of multiple RNA viruses, including SARS-CoV-2,  meant to treat mild COVID-19 outdoor patients in India.

Cipla receives final approval for generic version of Shire's Firazyr

Jul 14, 2020, at 09:39 pm

Mumbai/UNI:  Pharma major Cipla on Tuesday said that it has received final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA).

Cipla's generic version of Remdesivir to be cheapest among rivals: Report

Jul 09, 2020, at 05:39 am

Bengaluru/IBNS: Indian drug company Cipla has priced its generic version of Remdesivir, named Cipremi, at Rs 4,000 or USD 53.34 per 100 mg vial, making it the lowest priced versions of the COVID-19 treatment, a Reuters report said.

Cipla Limited launches generic remdesivir ‘Cipremi’ to fight COVID-19

Jun 22, 2020, at 05:26 pm

New Delhi: Homegrown pharma major Cipla Limited on Monday announced the launch of remdesivir under its brand name Cipremi.